

S2 Table. Factors for long-term responders

	OR (95% CI)	p-value
Complete response as best response	4.868 (2.170-10.921)	< 0.001
<i>de novo</i> stage IV	2.027 (0.913-4.505)	0.083
Docetaxel > 6	1.800 (0.401-8.077)	0.443
Hormone receptor positive	0.827 (0.390-1.755)	0.621
Presence of visceral metastasis	1.379 (0.641-2.965)	0.411
Disease-free survival > 5 years for relapsed disease	2.365 (0.514-10.889)	0.269
unexposed to anti-HER2 directed therapies prior to THP	15.738 (2.102-117.842)	0.007

CI, confidence interval; HER2, human epidermal growth factor receptor 2; OR, odds ratio; THP, docetaxel, trastuzumab, pertuzumab.